Pays: Irlande
Langue: anglais
Source: HPRA (Health Products Regulatory Authority)
Rabbit haemorrhagic disease, strain RHDV PHB 98
Pharmagal Bio s.r.o
QI08AA01
Rabbit haemorrhagic disease, strain RHDV PHB 98
minimum 1 PD90
Suspension for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Rabbits
rabbit haemorrhagic disease virus
Immunological - Inactivated Vaccine
Authorised
2008-11-10
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Anivac VHD Suspension for injection for rabbits 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of vaccine (0.5 ml) contains: _Active substances:_ Inactivated Rabbit Haemorrhagic Disease Virus strain RHDV PHB98 …… min. 1 PD 90 * _Adjuvant:_ Aluminium hydroxide gel ................................................................................. 1.3 mg _Excipients:_ Formaldehyde ……………………………………………………………… 0.55 mg Thiomersal ……………………………………………………………… 0.05 mg For a full list of excipients, see section 6.1. * Protective dose for minimum 90 % of vaccinated animals 3 PHARMACEUTICAL FORM Suspension for injection. Suspension of red-brown colour with easily shakeable sediment of inactivated RHDV adsorbed on aluminium hydroxide gel that forms 40-60 % of the vaccine if left undisturbed. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Rabbit. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For active immunisation of rabbits to prevent mortality caused by RHD virus Onset of immunity: 7 days Duration of immunity: 1 year based on field data without controlled challenge 4.3 CONTRAINDICATIONS None. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES No information is available on the use of the vaccine in seropositive animals including those with maternally derived antibodies; therefore in situations where high antibody levels are expected the vaccination protocol should be planned accordingly. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Lire le document complet